NewAmsterdam Pharma Company N.V. (NAMS) Revenue History
Annual and quarterly revenue from 2020 to 2025
Compound Annual Growth Rate (CAGR)
Loading revenue history...
NAMS Revenue Growth
Revenue Breakdown (FY 2022)
NAMS's revenue distribution by segment and geography for fiscal year 2022
By Product/Segment
NAMS Revenue Analysis (2020–2025)
As of May 17, 2026, NewAmsterdam Pharma Company N.V. (NAMS) generated trailing twelve-month (TTM) revenue of $22.6 million, reflecting modest growth of +2.1% year-over-year. The most recent quarter (Q1 2026) recorded $3.0 million in revenue, up 9400.0% sequentially.
Looking at the longer-term picture, NAMS's historical revenue data shows a 3-year CAGR of -39.7%. The company achieved its highest annual revenue of $102.7 million in 2022.
Revenue diversification analysis shows NAMS's business is primarily driven by License Revenue (100%). With over half of revenue concentrated in License Revenue, the company maintains significant focus in this area while developing other growth vectors.
When compared to Healthcare sector peers including ESPR (+61.1% YoY), MDGL (+256.8% YoY), and LNTH (+0.6% YoY), NAMS has underperformed the peer group in terms of revenue growth. Compare NAMS vs ESPR →
NAMS Revenue vs Peers
Revenue metrics vs comparable public companies
| Company | TTM Revenue | YoY Growth | 5Y CAGR | Op. Margin | Compare |
|---|---|---|---|---|---|
| NAMSCurrent | $23M | +2.1% | - | -1002.9% | |
 ESPR | $403M | +61.1% | +12.1% | 15.0% | |
 MDGL | $958M | +256.8% | - | -31.3% | |
 LNTH | $1.5B | +0.6% | +35.3% | 20.2% | |
 PFE | $62.6B | +1.4% | +8.5% | 24.7% | |
 MRK | $64.9B | +1.2% | +9.4% | 36.2% |
NAMS Historical Revenue Data (2020–2025)
| Year | Revenue | YoY % | Gross Profit | Gross Margin | Op. Income | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | $22.5M | -50.6% | $22.4M | 99.7% | $-225,683,000 | -1002.9% |
| 2024 | $45.6M | +223.4% | $45.6M | 100.0% | $-176,289,000 | -386.9% |
| 2023 | $14.1M | -86.3% | $14.1M | 100.0% | $-182,967,000 | -1298.6% |
| 2022 | $102.7M | - | $102.7M | 100.0% | $-3,557,000 | -3.5% |
| 2021 | $0 | - | $0 | - | $-34,977,000 | - |
| 2020 | $0 | - | $0 | - | $-6,632,054 | - |
See NAMS's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs NAMS Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare NAMS vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonNAMS — Frequently Asked Questions
Quick answers to the most common questions about buying NAMS stock.
Is NAMS's revenue growth accelerating or slowing?
NAMS revenue growth slowed to +2.1%, below the 5-year CAGR of N/A. TTM revenue is $23M. The deceleration marks a shift from historical growth rates.
What is NAMS's long-term revenue growth rate?
NewAmsterdam Pharma Company N.V.'s 5-year revenue CAGR of N/A reflects the variable expansion pattern. Current YoY growth of +2.1% is near this long-term average.
How is NAMS's revenue distributed by segment?
NAMS reports revenue by product line and geographic region. Annual and quarterly breakdowns from 2020-2025 are available for download. Segment mix reveals concentration and diversification trends.